A JAMA research letter published August 30 looks at “Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 [Pfizer] and mRNA-1273 [Moderna].” The corresponding author for this research letter is Deborah Steensels, PharmD, Ph.D., Department of Laboratory Medicine, Ziekenhuis Oost-Limburg, Belgium. Her work has included papers on Covid-19 related kidney damage, SARS-CoV-2 shedding in dialysis patients, venereal disease screening, and testing for types of influenza. While some critics downplay the findings, others indicate Moderna’s mRNA-1273 vaccine product outshines Pfizer’s BNT162b2.
Humoral versus Cellular Immune Response
In a perhaps outdated assertion, the researchers note that both vaccines have an efficacy rate of over 90% in preventing illness. Their aim is to directly compare humoral immune responses to the vaccines, something never done to their knowledge. Contrasted with immune reactions within cells, this type of response involves extra-cellular substances such as antibodies, proteins, and peptides; “humors” in this context refers to body fluid. The research involved health care workers in Belgium who took either the Pfizer-BioNTech product...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).